消息面上，今年上半年，北海康成实现收益2224.8万元，同比减少50.33%；期内溢利5923.8万元，去年 同期则取得亏损2.47亿元，实现扭亏为盈。公告指，收入减少主要由于公司原计划于2021年战略性专注 于罕见病，于2024年底贺俪安分销协议终止后贺俪安在中国台湾销售停止。除贺俪安在中国台湾的销售 外，公司收益较2024年同期减少170万元或6.9%，主要由于2025年上半年北海康成实施积极存货管理， 并在渠道中减少迈芮倍的库存。 北海康成-B(01228)涨超9%，该股今年以来涨幅巨大，年内累计涨幅高达16倍。截至发稿，涨8.6%，报 2.4港元，成交额1613.03万港元。 今年8月，北海康成宣布与百洋医药（301015）达成股份认购协议，根据协议，百洋医药将斥资1亿港元 认购北海康成股份。与此同时，北海康成与百洋医药双方通过签订独家商业化服务协议，进一步深化战 略协同。根据协议，百洋医药旗下子公司将获得北海康成旗下特定产品在中国内地、香港及澳门地区的 推广权。此外，国家医保局8月12日公布商保创新药目录初审名单中，北海康成三款罕见病产品均通过 了商保创新药目录的形式审查，包括今年5月获批上市的用于 ...

今年8月，北海康成宣布与百洋医药达成股份认购协议，根据协议，百洋医药将斥资1亿港元认购北海康 成股份。与此同时，北海康成与百洋医药双方通过签订独家商业化服务协议，进一步深化战略协同。根 据协议，百洋医药旗下子公司将获得北海康成旗下特定产品在中国内地、香港及澳门地区的推广权。此 外，国家医保局8月12日公布商保创新药目录初审名单中，北海康成三款罕见病产品均通过了商保创新 药目录的形式审查，包括今年5月获批上市的用于12岁及以上青少年和成人I型和Ⅲ型戈谢病患者的长期 酶替代产品戈芮宁（注射用维拉苷酶β）等。 北海康成-B(01228)涨超9%，该股今年以来涨幅巨大，年内累计涨幅高达16倍。截至发稿，涨8.6%，报 2.4港元，成交额1613.03万港元。 消息面上，今年上半年，北海康成实现收益2224.8万元，同比减少50.33%；期内溢利5923.8万元，去年 同期则取得亏损2.47亿元，实现扭亏为盈。公告指，收入减少主要由于公司原计划于2021年战略性专注 于罕见病，于2024年底贺俪安分销协议终止后贺俪安在中国台湾销售停止。除贺俪安在中国台湾的销售 外，公司收益较2024年同期减少170万元或6.9%，主要 ...

FF301 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北海康成製藥有限公司（於開曼群島註冊成立之有限公司） 呈交日期: 2025年9月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01228 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 第 1 頁 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依賴該等內 容而引致的任何損失承擔任何責任。 CANbridge Pharmaceuticals Inc. 北海康成製藥有限公司 股份計劃 根據上市規則第17.07(1)(d)、 17.03(3)及17.09(3)條，本公司謹此提供以下有關股份計劃（即首次公開 發售前股權激勵計劃、首次公開發售後受限制股份單位計劃及首次公開發售後購股權計劃）的其他資 料。 • 本公司已披露以下於報告期間根據首次公開發售前股權激勵計劃行使授出的購股權及根據首次 公開發售後受限制股份單位計劃歸屬受限制股份單位。根據上市規則第17.07(1)(d)條，緊接相關 行使或歸屬日期前，該行使或歸屬日期（倘適用）及股份的加權平均收市價如下： （於開曼群島註冊成立的有限公司） （股份代號：1228） 有關2024年年報的補充公告 茲提述本公司截至2024年12月31日止年度的年度報告（「2024年年報」）。除另有提供者外，本公告所 用詞彙與2024年年報所使用者具有相同涵義。 撇銷 ...

Group 1: Hong Kong Stocks Performance - BYD Electronics (00285) rose over 7%, reporting a nearly 14% year-on-year increase in net profit for the first half of 2025, with positive progress in AI data center business [1] - Beihai Kangcheng-B (01228) surged over 11%, achieving profitability in the first half of the year and recently forming a strategic partnership with Baiyang Pharmaceutical [1] - MicroPort Medical (00853) increased over 11%, with a reported loss of $46.602 million for the first half of 2025, a 51.9% reduction in loss year-on-year [1] - Bank of China Hong Kong (02388) rose over 6%, reporting a net profit of HKD 22.12 billion for the first half of 2025, with an increase in net trading income year-on-year [1] - UBTECH (09880) increased over 4%, announcing a strategic partnership agreement worth $1 billion with international investment firm Infini Capital [1] - Gold stocks performed well, with China Silver Group (00815) up over 8%, Zhaojin Mining (01818) up over 7%, Shandong Gold (01787) up over 6%, Chifeng Jilong Gold (06693) up over 6%, and Zijin Mining (02899) up over 6%, driven by rising gold prices due to increased interest rate cut expectations [1] Group 2: Chinese Companies' Financial Results - China Communications Construction (01800) fell over 5%, reporting a 16.9% year-on-year decrease in net profit for the first half of 2025 and not declaring an interim dividend [2] - Evergrande Property (06666) declined over 3%, with a 5.6% year-on-year drop in net profit for the first half of the year, with management expressing pessimism about economic benefits from Evergrande Group [2] - Zoomlion Heavy Industry (01157) rose over 2%, reporting a more than 20% year-on-year increase in net profit for the first half of 2025, with institutions optimistic about export growth in the second half [2] - Midea Group (00300) increased over 2%, reporting a 25.04% year-on-year increase in net profit for the first half of 2025 and proposing an interim dividend of HKD 5 per 10 shares [2] Group 3: US Stocks Performance - Autodesk (ADSK.US) rose 9.09%, reporting a 17% year-on-year revenue increase for the second fiscal quarter and raising its full-year revenue and adjusted EPS guidance [3] - Gap (GAP.US) increased 1.52%, with revenue slightly below market expectations for the second fiscal quarter, and management indicated that tariffs may pressure annual gross margins [3] - Marvell Technology (MRVL.US) fell 18.60%, reporting record revenue of $2.01 billion for the second quarter, a 58% year-on-year increase, but provided a Q3 revenue guidance slightly below expectations [3] - Alibaba (BABA.US) surged 12.90%, with a market value increase of $36.7 billion overnight, reporting an 18% year-on-year decline in Non-GAAP net profit, but strong resilience in core business [3] - Ambarella (AMBA.US) rose 16.78%, providing strong guidance for Q3 revenue, expected to be between $100 million and $108 million, reflecting continued growth in edge AI demand [3] - IREN Ltd (IREN.US) increased 14.93%, exceeding expectations in its fourth-quarter earnings report and announcing a priority partnership with NVIDIA [3] Group 4: Other Notable Stocks - Dell Technologies (DELL.US) fell 8.88%, reporting that its infrastructure division's operating profit margin was below expectations [4] - Affirm Holdings (AFRM.US) rose 10.59%, reporting better-than-expected revenue and profit for the fourth fiscal quarter [4] - TryHard Holdings (THH.US) declined 9.80%, issuing 1.5 million shares at $4 each, at the lower end of the pricing range [5] - GrowHub (TGHL.US) increased 1.48%, issuing 3.8 million shares at $4 each, also at the lower end of the pre-set pricing range [5]

消息面上，北海康成发布中期业绩，上半年收益2224.8万元，同比减少50.33%；期内溢利5923.8万元， 去年同期则取得亏损2.47亿元，实现扭亏为盈。公告称，收入减少主要由于公司原计划于2021年战略性 专注于罕见病，于2024年底贺俪安分销协议终止后贺俪安在中国台湾销售停止。除贺俪安在中国台湾的 销售外，公司收益较2024年同期减少170万元或6.9%，主要由于2025年上半年北海康成实施积极存货管 理，并在渠道中减少迈芮倍的库存。 值得注意的是，2025年8月，北海康成宣布与百洋医药（301015）达成股份认购协议，根据协议，百洋 医药将斥资1亿港元认购北海康成股份。与此同时，北海康成与百洋医药双方通过签订独家商业化服务 协议，进一步深化战略协同。根据协议，百洋医药旗下子公司将获得北海康成旗下特定产品在中国内 地、香港及澳门地区的推广权。 北海康成-B(01228)绩后涨超12%，截至发稿，涨9.48%，报2.54港元，成交额1031.41万港元。 ...

Core Viewpoint - Beihai Kangcheng-B (01228) experienced a significant stock price increase of over 12% following the release of its interim results, indicating positive market sentiment despite a decline in revenue [1] Financial Performance - For the first half of the year, the company reported revenue of 22.248 million, a decrease of 50.33% year-on-year [1] - The company achieved a profit of 59.238 million, compared to a loss of 247 million in the same period last year, marking a turnaround to profitability [1] - Revenue decline was primarily attributed to the company's strategic focus on rare diseases initiated in 2021, with the termination of the distribution agreement for the product "He Li An" in Taiwan by the end of 2024 [1] - Excluding the sales of "He Li An" in Taiwan, the company's revenue decreased by 1.7 million or 6.9% compared to the same period in 2024, mainly due to proactive inventory management and reduced stock of "Mai Ru Bei" in the channels [1] Strategic Developments - In August 2025, the company announced a share subscription agreement with Baiyang Pharmaceutical, where Baiyang will invest 100 million Hong Kong dollars to subscribe for shares in Beihai Kangcheng [1] - The agreement includes an exclusive commercialization service contract, enhancing strategic collaboration between the two companies [1] - A subsidiary of Baiyang Pharmaceutical will gain promotional rights for specific products of Beihai Kangcheng in mainland China, Hong Kong, and Macau [1]

Group 1 - The company reported a profit of approximately RMB 306.5 million for the first half of 2025, reversing a loss of RMB 247.3 million from the same period in 2024, primarily due to increased other income and reduced sales, distribution, R&D, and administrative expenses, partially offset by decreased revenue [1] - Adjusted loss decreased by RMB 178.9 million or 82.7% to RMB 37.4 million for the first half of 2025, compared to an adjusted loss of RMB 216.2 million for the first half of 2024 [1] - The adjusted loss was derived from the reported profit of RMB 59.2 million, excluding the impact of share-based payment expenses, write-offs of right-of-use assets, and lease termination gains/losses [1] Group 2 - The company began a strategic partnership with Baiyang Pharmaceutical in August 2025, appointing its subsidiaries as exclusive contract sales organizations for marketing services and distribution in mainland China, Hong Kong, and Macau, with a strategic cooperation fee of RMB 50 million [2] - Baiyang Pharmaceutical's subsidiary subscribed for 74,971,468 shares of the company, representing 14.99% of the enlarged issued share capital, for a total consideration of approximately HKD 100 million [2] - Despite challenges in the first half of 2025, the company remains optimistic for the second half, focusing on streamlining its product line and enhancing capital efficiency, expecting improved performance through deeper collaboration with Baiyang Pharmaceutical [2]

Group 1 - The company reported a profit of approximately RMB 306.5 million for the first half of 2025, reversing a loss of RMB 247.3 million from the same period in 2024, primarily due to increased other income and reduced sales, distribution, R&D, and administrative expenses, partially offset by a decrease in revenue [1] - The adjusted loss for the period decreased by RMB 178.9 million or 82.7% to RMB 37.4 million, compared to an adjusted loss of RMB 216.2 million for the first half of 2024 [1] - The adjusted loss was derived from the reported profit of RMB 59.2 million, excluding the impact of share-based payment expenses, write-offs of right-of-use assets, and lease termination gains/losses [1] Group 2 - The company began a strategic partnership with Baiyang Pharmaceutical in August 2025, appointing its subsidiaries as exclusive contract sales organizations for marketing services and as exclusive distributors for specific products in mainland China, Hong Kong, and Macau, with a strategic cooperation fee of RMB 50 million [2] - Baiyang Pharmaceutical's subsidiary subscribed for 74,971,468 shares of the company, representing 14.99% of the enlarged issued share capital, with a total consideration of approximately HKD 100 million [2] - Despite challenges in the first half of 2025, the company remains optimistic about the second half, focusing on streamlining its product line and enhancing capital efficiency, expecting improved operational foundations and performance through the deepened collaboration with Baiyang Pharmaceutical [2]

北海康成-B(01228)发布截至2025年6月30日止6个月中期业绩，该集团取得收益2224.8万元，同比减少 50.33%;期内溢利5923.8万元，去年同期则取得亏损2.47亿元;每股盈利0.14元。 公告称，收入减少主要由于本公司原计划于2021年战略性专注于罕见病，于2024年底贺俪安分销协议终 止后贺俪安在台湾销售停止。除贺俪安在台湾的销售外，我们的收益较2024年同期减少170万元或 6.9%，主要由于2025年上半年北海康成实施积极存货管理，并在渠道中减少迈芮倍的库存。 ...